Toll Free: 1-888-928-9744
Published: Mar, 2015 | Pages:
33 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Purdue Pharma L.P. - Product Pipeline Review - 2015 Summary Global Markets Direct's, 'Purdue Pharma L.P. - Product Pipeline Review - 2015', provides an overview of the Purdue Pharma L.P.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Purdue Pharma L.P.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Purdue Pharma L.P. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Purdue Pharma L.P.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Purdue Pharma L.P.'s pipeline products Reasons to buy - Evaluate Purdue Pharma L.P.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Purdue Pharma L.P. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Purdue Pharma L.P.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Purdue Pharma L.P. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Purdue Pharma L.P. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Explore the dormant and discontinued projects of Purdue Pharma L.P. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of table 4 List of Figures 4 Purdue Pharma L.P. Snapshot 5 Purdue Pharma L.P. Overview 5 Key Information 5 Key Facts 5 Purdue Pharma L.P. - Research and Development Overview 6 Key Therapeutic Areas 6 Purdue Pharma L.P. - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Pipeline Products - Combination Treatment Modalities 10 Pipeline Products - Partnered Products 11 Partnered Products/Combination Treatment Modalities 12 Pipeline Products - Out-Licensed Products 13 Out-Licensed Products/Combination Treatment Modalities 14 Purdue Pharma L.P. - Pipeline Products Glance 15 Purdue Pharma L.P. - Late Stage Pipeline Products 15 Pre-Registration Products/Combination Treatment Modalities 15 Phase III Products/Combination Treatment Modalities 16 Purdue Pharma L.P. - Clinical Stage Pipeline Products 17 Phase II Products/Combination Treatment Modalities 17 Purdue Pharma L.P. - Drug Profiles 18 (naloxone hydrochloride + oxycodone hydrochloride) ER 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 PRC-062 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 V-116517 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Purdue Pharma L.P. - Pipeline Analysis 22 Purdue Pharma L.P. - Pipeline Products by Target 22 Purdue Pharma L.P. - Pipeline Products by Route of Administration 23 Purdue Pharma L.P. - Pipeline Products by Molecule Type 24 Purdue Pharma L.P. - Pipeline Products by Mechanism of Action 25 Purdue Pharma L.P. - Recent Pipeline Updates 26 Purdue Pharma L.P. - Dormant Projects 27 Purdue Pharma L.P. - Discontinued Pipeline Products 28 Discontinued Pipeline Product Profiles 28 licostinel 28 Purdue Pharma L.P. - Company Statement 29 Purdue Pharma L.P. - Locations And Subsidiaries 30 Head Office 30 Other Locations & Subsidiaries 30 Appendix 32 Methodology 32 Coverage 32 Secondary Research 32 Primary Research 32 Expert Panel Validation 32 Contact Us 32 Disclaimer 33
List of Tables Purdue Pharma L.P., Key Information 5 Purdue Pharma L.P., Key Facts 5 Purdue Pharma L.P. - Pipeline by Indication, 2015 7 Purdue Pharma L.P. - Pipeline by Stage of Development, 2015 8 Purdue Pharma L.P. - Monotherapy Products in Pipeline, 2015 9 Purdue Pharma L.P. - Combination Treatment Modalities in Pipeline, 2015 10 Purdue Pharma L.P. - Partnered Products in Pipeline, 2015 11 Purdue Pharma L.P. - Partnered Products/ Combination Treatment Modalities, 2015 12 Purdue Pharma L.P. - Out-Licensed Products in Pipeline, 2015 13 Purdue Pharma L.P. - Out-Licensed Products/ Combination Treatment Modalities, 2015 14 Purdue Pharma L.P. - Pre-Registration, 2015 15 Purdue Pharma L.P. - Phase III, 2015 16 Purdue Pharma L.P. - Phase II, 2015 17 Purdue Pharma L.P. - Pipeline by Target, 2015 22 Purdue Pharma L.P. - Pipeline by Route of Administration, 2015 23 Purdue Pharma L.P. - Pipeline by Molecule Type, 2015 24 Purdue Pharma L.P. - Pipeline Products by Mechanism of Action, 2015 25 Purdue Pharma L.P. - Recent Pipeline Updates, 2015 26 Purdue Pharma L.P. - Dormant Developmental Projects,2015 27 Purdue Pharma L.P. - Discontinued Pipeline Products, 2015 28 Purdue Pharma L.P., Other Locations 30 Purdue Pharma L.P., Subsidiaries 31
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.